PTK2 and metabolic dysfunction-associated steatohepatitis: Taken together, all these findings illustrated that DUSP22 could alleviate lipid accumulation, inflammation, hepatic fibrosis, and NASH-HCC progression, primarily relying on the FAK inactivation.